Project Grant R01AI202268
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $572K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bozeman, MT 59717, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Montana State University $560,708 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into the pathogenesis of neurobrucellosis. The award supports a five-year research project through July 31, 2031, examining how Brucella bacteria cross the blood-brain barrier, colonize the brain, and cause neurobrucellosis—the most severe complication of brucella infection in humans....
- The National Institute of Allergy and Infectious Diseases awarded the University of Montana $147,000 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop inter-strain recombinants of human cytomegalovirus as an in vitro model of in vivo genetic diversity. The project investigates genetic correlates of phenotypic variation in HCMV by generating and characterizing a recombinant library created through coinfection of cells with two genetically...
- The National Institute of Allergy and Infectious Diseases awarded Montana State University $217,500 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize how HLB (beta-toxin) expression affects methicillin-resistant Staphylococcus aureus (MRSA) ability to evade human polymorphonuclear leukocyte (PMN/neutrophil) responses. The research investigates the mechanism by which HLB reduces MRSA cytotoxicity against human PMNs by inhibiting...
- The National Institute of Allergy and Infectious Diseases awarded $100,228 to Purdue University on December 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of La Crosse virus glycoprotein GN cytoplasmic tail in coordinating ribonucleoprotein assembly. La Crosse virus is the leading cause of pediatric encephalitis in the United States and can cause seizures and long-term neurological complications, yet no vaccines or antiviral therapies...
- The National Institute of Allergy and Infectious Diseases awarded New Mexico State University $146,671 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2026, for a project grant (R16AI201108) investigating the link between immunometabolism and epigenetics in the malaria vector mosquito Anopheles stephensi. The project employs a multi-omics approach integrating metabolomic, epigenomic, and transcriptomic data to establish mechanistic linkages between...
- Federal Grant Award Summary The University of Montana received a $143,094 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. This award supports basic biomedical research focused on characterizing a ubiquitin binding domain (UBD) in RIOK3, an innate immune protein essential for initiating interferon responses to viral infections such as Rift...
- The National Institute of Allergy and Infectious Diseases awarded La Jolla Institute for Immunology $279,000 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map anti-filovirus humoral immune responses in broadly seroreactive individuals. The award funds detailed analysis of antibody repertoires from 23 individuals in the Democratic Republic of the Congo who demonstrate extraordinarily broad and strong antibody responses against multiple filovirus...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $480,000 on September 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular basis for arboviral fitness in vector and reservoir hosts. The research examines how arboviruses replicate across evolutionarily distant hosts—insects and vertebrates—despite showing high specificity in their transmission cycles. Using alphaviruses as a...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $725,778 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate alphaherpesvirus axonal transport and neuroinvasion mechanisms. The research deciphers how neuroinvasive herpesviruses such as herpes simplex virus type 1 and pseudorabies virus invade the nervous system to establish lifelong latent infections; identifies intrinsic barriers to neural...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $771,510 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to profile La Crosse virus genetic diversity in human neuroinvasive disease cases and peridomestic mosquitoes in Western North Carolina. The research establishes and executes a prospective cohort study collecting serum and cerebrospinal fluid samples from La Crosse virus patients...